Axol Bioscience Ltd.

We're hitting the ground running this new year as we prepare for our first conference of the year, SLAS 2025 International Conference in San Diego later this month. We’re excited to kick off 2025 with our first event of the year – the SLAS 2025 International Conference in San Diego! 📅 When: January 25-29, 2025 📍 Where: San Diego Convention Center, San Diego, CA With this year’s theme being, "Curiosity Igniting Innovation," we invite you to let your curiosity lead you to our booth to explore how we’re contributing to the cutting-edge work within the iPSC space and the industry at large. As leaders in the field, we’re proud to showcase our innovative products and services that are driving advances in disease modeling and drug discovery. Whether you're working in neuroscience, cardiology, our innovative solutions are designed to support your research, Come find us at Booth 127 and let's have a conversation. We look forward to engaging with fellow scientists, researchers, and industry professionals to discuss new technologies, share insights, and explore opportunities for collaboration. Also, we'll be presenting some posters at the conference and if you want a head start on reading up on some of our work, you can view them here https://hubs.la/Q031fmvs0 or alternatively contact us at operations@axolbio.com if you have any questions. #SLAS2025 #iPSC #LifeSciences #BiomedicalResearch #CellManufacturing #DiseaseModeling #DrugDiscovery #FunctionalAssays #ScientificCommunity #SLAS #SanDiego2025

While the Christmas may be over, we’re still in the giving spirit. As we step into 2025, we have a special gift for you, our valued customers. As always, this year we're pledging to support the iPSC community, helping researchers to unlock the benefits of iPSC technology for better human disease models. As part of this pledge, we're making it easier and more affordable to access and use market-leading iPSC technology. That includes those new to iPSCs, researchers already engaged with iPSC technology, and groups looking to scale up in size and complexity. At Axol, we believe in the power of partnership and staying committed to providing high-quality products at the best value. As a token of appreciation for your continued trust and support, this is our gift to you — a promise of no price rises for the entire year. Whether you're looking to use iPSCs for the first time or want to scale up your in vitro projects, let us know what we can do to help by contacting us at operations@axolbio.com. We look forward to continuing our journey together in the new year and beyond. #iPSCs #StemCells #DrugDiscovery #Biotech #NewYear2025 #CustomerAppreciation #Manufacturing #NoPriceIncreases

From everyone at Axol Bioscience, we'd like to wish a Happy New Year to our customers, collaborators and iPSC community. We're looking forward to an even more exciting year supporting the iPSC market! #iPSCs #HappyNewYear #2025

From all of us at Axol Bioscience, we wish you a Merry Christmas and hope the festive period gives you time to rest, recharge and spend time with your loved ones. #iPSCs #SeasonsGreetings #MerryChristmas

We're logging off! As the year comes to a close, it's a good time to remember that everyone deserves a break including our collaborators, clients and our team of dedicated scientists who have worked throughout the year to push forward drug discovery. The holiday season is the perfect time to pause, recharge, and spend quality time with loved ones. At Axol, we are incredibly proud of what we’ve accomplished this year, and we look forward to continuing our work together in the new year. But for now, it’s time for some well-earned rest. Wishing all of our colleagues, partners, and customers a peaceful Christmas and New Year season filled with joy. See you in 2025, where we will return ready to tackle new challenges and continue making a difference in the industry. #Rest #HolidayBreak #Teamwork #Recharge

At Axol, we strive to enable scientific discovery around the globe by providing the tools and solutions that drive innovation. Our mission is to support researchers, scientists, and institutions in building better models of human disease to advance and de-risk drug discovery which will ultimately improve lives. As we reflect on the year, we would like to say a huge thank you to all our customers and partners worldwide. Your trust, collaboration, and engagement have been invaluable to us, and we are proud to be part of the incredible work you're doing. We look forward to continuing our partnerships and creating more opportunities for meaningful progress in the coming year. Wishing you a Merry Christmas and a wonderful New Year. Stuart Prime – Strategic Partnership & Collaboration Manager

It's that time of year again when people are beginning to wind down for the year. We truly hope that you take some time to take a break, relax, and reflect on all the great things that have taken place both professionally and personally. In true Axol fashion, we are back again to share with you all that we got up to this December. Our key December highlights included: 1. Our new news piece showcasing Tessara Therapeutics with us collaborate to develop iPSC-derived 3D human brain micro-tissues for drug discovery applications 2. Axol being awarded the Scottish SMART Grant to support our continued work in ALS research 3. We were at the 35th International Symposium on ALS/MND and presented a new poster 4. Phenocell, a part of the Axol Bioscience family, and Amarna Therapeutics were Awarded Eurostars Grant to Assess a Gene Therapy for Dry AMD 5. Our CEO, Liam Taylor's EOY review is now available to read 6. Our upcoming conferences You will find more details on each of these in our December Newsletter below. Enjoying the content? Make sure to subscribe to our newsletter- we now have over 3,000 subscribers! #iPSCs #StemCells #MonthlyNewsletter

As we gear up for the start of 2025, our CEO Liam Taylor would like to share his 2024 End-of-Year Review. It's been a monumental year, and we're delighted to see the industry shifting towards advanced in vitro technology for drug discovery. Across the year, we've engaged with platform providers and biopharma organizations, launched new products, saw positive shifts in the regulatory space, presented new posters, attended regular conferences, held webinars acquired Phenocell, a leading biotechnology company we are completely aligned with in mission and values, and established ourselves as the leaders in human iPSC technology on a global scale. Our CEO Liam Taylor has rounded up his key highlights in this End of Year Review, following on from his Summer Review. Click here to read Liam's End of Year Review and learn more about how this year has truly been a year of iPSCs: https://hubs.la/Q030cS170 And make sure to contact us in 2025 and let us know how can we help with your iPSC projects at operations@axolbio.com. #iPSCs #PoweredByAxol #OrganOnAChip #DrugDiscovery #HumaniPSCs

FDA Modernization 3.0: A Step Toward Animal-Free Testing and Advanced In Vitro Models The FDA Modernization Act 3.0 being passed by the US Senate marks a significant milestone in the shift toward animal-free testing in drug development. As the FDA takes steps to modernize its regulations, microphysiological systems (MPS) and advanced in vitro systems like iPSC-based models are becoming central to this transformation. It was stated in a press release that "The FDA Modernization Act 3.0 is a bipartisan effort to reduce unnecessary animal testing while advancing scientific innovation. By fully implementing FDAMA 3.0, drug development can be both more humane and more efficient, ultimately leading to faster and more reliable treatments for patients." The integration of iPSC models into drug discovery and disease modeling offers the potential for more accurate, human-relevant data while reducing reliance on animal testing. These models allow for greater translational relevance, de-risking drug discovering and providing the platform for better understanding of human disease. The FDA Modernization Act 3.0 will pave the way for wider adoption of microphysiological platforms that could revolutionize the pharmaceutical industry. https://hubs.la/Q03013Ch0. As we look toward 2025, the continued advancement of iPSC models and MPS will be pivotal in shaping the future of drug development. We, as others in the industry, will continue to stay tuned for more updates as this space evolves. #FDA #iPSC #MPS #DrugDiscovery #AnimalFreeTesting #Biotech #FDAModernization #ScienceInnovation

*Excellent Webinar Alert* With the industry's push towards better human models of disease, the question remains, what constitutes an ideal model? We recently did a 2-part webinar series speaking about this which is now available to access. As we know, neurodegenerative diseases are a major global health issue, yet the drug development process is notoriously slow with 99.6% of potential new therapies for Alzheimer's Disease (AD) alone failing and thus, not reaching the market. With such high failure rates, there is an urgent need for better human-relevant models of such diseases in order to de-risk drug discovery and improve the bench-to-clinic translation gap. But what actually constitutes an ideal model and how do iPSCs meet these characteristics? In a recent 2-part webinar, our Senior Scientific Support Manager Dr. Steven Broadbent spoke in detail about this. In the first webinar, he spoke about how iPSCs constitute a good fit towards achieving better human models of disease compared to other models. He also discussed how we at Axol are using iPSCs to build these human-relevant models and how previously we have used them to build in vitro models to answer some specific disease-related questions. Of course, with most things in science, there are existing challenges within this space which includes the challenge of translating these iPSCs into more complex models. This was also discussed in the first webinar. In the second webinar, Dr. Steven detailed some of the practical case studies we have done specifically in Amyotrophic Lateral Sclerosis and AD in creating these more complex physiologically relevant human disease models. If you missed the webinars, not to worry you can watch them here: https://hubs.la/Q02_qrL40 If you have any questions, contact us at operations@axolbio.com. #iPSCs #learnwithAxol #Neurodegenerativeresearch #AlzheimersDisease #ALS